Heart failure & cardiomyopathies
Sodium-Glucose Co-Transporter 2 Inhibitors in Acute Heart Failure: Real-World Prescription Trends and Outcomes Analysis
Authors' conclusion
The prescription and initiation of SGLT2 inhibitors during hospitalization are associated with improved post-discharge outcomes in patients with ADHF, irrespective of LVEF.
Study context
- Population
- Patients admitted with acute decompensated heart failure (HF), Nihon University Itabashi Hospital (Tokyo, Japan), 2018–2022
- Participants
- 1,108 patients
- Exposure
- SGLT2 inhibitor prescription during hospitalisation vs none
- SGLT2in = 289
- non-SGLT2in = 819reference
- Outcome
- Death and rehospitalization for HF after discharge (composite)
- Follow-up
- Median 366 days (IQR: 116, 614)
Methodological detailspost hoc analysis, single-centre
- Post hoc analysis
- Single-centre
Main finding
As reported in the abstract
Patients reaching the primary endpoint (overall)
458
41.3%
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Composite events, by LVEF subgroupSGLT2i vs non-SGLT2i · HFrEF (n = 413) | P = 0.044 |
| Composite events, by LVEF subgroupSGLT2i vs non-SGLT2i · HF with mildly reduced EF (n = 226) | P = 0.013 |
| Composite events, by LVEF subgroupSGLT2i vs non-SGLT2i · HFpEF (n = 466) | P = 0.001 |
- Composite events, SGLT2i initiated during hospitalization vs not using SGLT2i — Also significant in left ventricular ejection fraction (LVEF) subgroups (HFrEF, HF with mildly reduced ejection fraction (EF), HFpEF) · overall
- P = 0.005, P = 0.032, and P = 0.004, respectively · P < 0.001
SGLT2i prescription trend
- Increasing trend in SGLT2i prescription since 2021
Original publication
Sodium-Glucose Co-Transporter 2 Inhibitors in Acute Heart Failure: Real-World Prescription Trends and Outcomes Analysis. ESC Heart Fail. Published 28 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →